Lederman Emily E, Hope Jacob M, King Michael R
Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, United States.
Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, United States.
Front Oncol. 2018 Oct 29;8:410. doi: 10.3389/fonc.2018.00410. eCollection 2018.
Metastasis through the bloodstream contributes to poor prognosis in many types of cancer. A unique approach to target and kill colon, prostate, and other epithelial-type cancer cells in the blood has been recently developed that uses circulating leukocytes to present the cancer-specific, liposome-bound Tumor Necrosis Factor (TNF)-related apoptosis inducing ligand () on their surface along with - adhesion receptors. This approach, demonstrated both with human blood and in mice, mimics the cytotoxic activity of natural killer cells. The resulting liposomal TRAIL-coated leukocytes hold promise as an effective means to neutralize circulating tumor cells that enter the bloodstream with the potential to form new metastases. The computational biology study reported here examines the mechanism of this effective signal delivery, by considering the kinetics of the coupled reaction cascade, from TRAIL binding death receptor to eventual apoptosis. In this study, a collision of bound TRAIL with circulating tumor cells (CTCs) is considered and compared to a prolonged exposure of CTCs to soluble TRAIL. An existing computational model of soluble TRAIL treatment was modified to represent the kinetics from a diffusion-limited 3D reference frame into a 2D collision frame with advection and adhesion to mimic the - and membrane bound TRAIL treatment. Thus, the current model recreates the new approach of targeting cancer cells within the blood. The model was found to faithfully reproduce representative observations from experiments of liposomal TRAIL treatment under shear. The model predicts apoptosis of CTCs within 2 h when treated with membrane bound TRAIL, while apoptosis in CTCs treated with soluble TRAIL proceeds much more slowly over the course of 10 h, consistent with previous experiments. Given the clearance rate of soluble TRAIL , this model predicts that the soluble TRAIL method would be rendered ineffective, as found in previous experiments. This study therefore indicates that the kinetics of the coupled reaction cascade of liposomal - and membrane bound TRAIL colliding with CTCs can explain why this new approach to target and kill cancer cells in blood is much more effective than its soluble counterpart.
通过血液循环发生的转移导致多种癌症的预后不良。最近开发了一种独特的方法来靶向并杀死血液中的结肠、前列腺和其他上皮型癌细胞,该方法利用循环白细胞在其表面呈现与脂质体结合的癌症特异性肿瘤坏死因子(TNF)相关凋亡诱导配体(TRAIL)以及β2 - 整合素粘附受体。这种方法在人体血液和小鼠中均得到了验证,模拟了自然杀伤细胞的细胞毒性活性。由此产生的脂质体包裹TRAIL的白细胞有望成为一种有效的手段,用于中和进入血液循环并有可能形成新转移灶的循环肿瘤细胞。本文报道的计算生物学研究通过考虑从TRAIL结合死亡受体到最终凋亡的偶联反应级联动力学,研究了这种有效信号传递的机制。在本研究中,考虑了结合TRAIL与循环肿瘤细胞(CTC)的碰撞,并将其与CTC长时间暴露于可溶性TRAIL的情况进行比较。对现有的可溶性TRAIL治疗计算模型进行了修改,以表示从扩散受限的三维参考系到具有平流和粘附的二维碰撞框架的动力学,以模拟β2 - 整合素和膜结合TRAIL治疗。因此,当前模型重现了在血液中靶向癌细胞的新方法。该模型被发现能够忠实地重现脂质体TRAIL治疗在剪切力作用下实验的代表性观察结果。该模型预测,当用膜结合TRAIL处理时,CTC在2小时内会发生凋亡,而用可溶性TRAIL处理的CTC在10小时的过程中凋亡进展要慢得多,这与先前的实验一致。考虑到可溶性TRAIL的清除率,该模型预测可溶性TRAIL方法将无效,正如先前实验中所发现的那样。因此,本研究表明,脂质体β2 - 整合素和膜结合TRAIL与CTC碰撞的偶联反应级联动力学可以解释为什么这种在血液中靶向并杀死癌细胞的新方法比其可溶性对应方法更有效。